
Monday, August 22, 2016 4:28:14 PM
"Veeva’s industry cloud solutions gain momentum as companies unify business processes for faster time to market and greater compliance
As life sciences companies continue their transition from legacy on-premises and horizontal cloud software to industry-specific cloud applications, Veeva Systems (NYSE:VEEV) is strengthening its position as a fast-growing, strategic vendor in the industry across its most critical functions. According to Gartner, Veeva’s extensive cloud-based multitenant software solution set across research and development (R&D) and commercial is building the company into a strategic-level vendor for global pharma and biotech clients.1
Increased complexity in life sciences – from global stakeholder ecosystems to regulatory requirements – is driving organizations to streamline operations to be more efficient and agile. This is in an effort to accelerate innovation and get products to market faster and more effectively on a global scale. Organizations are implementing new cloud approaches to improve collaboration and provide smarter ways of working.
As a result, the industry is increasingly relying on Veeva’s applications to streamline their global business operations, with 35 of the top 50 pharmaceutical companies using Veeva Vault to unify their processes and content on a single platform in the areas of commercial, clinical, regulatory, quality and medical.2 Customers are turning to Veeva to help them improve overall business agility, compliance, and risk mitigation.
Over the next five years, Gartner expects migration to multichannel marketing to strengthen and grow within pharma and recognized Veeva as one of only two vendors to offer complete CRM products, support, and services across most of the globe.3 Veeva is in the market share leadership position of the pharma CRM vendor landscape.4
According to IDC Health Insights, Veeva’s continued momentum in the sales and marketing space has strengthened its leadership in the industry.5 “Veeva has leveraged its strong position in the life science CRM space to provide an optimized omni-channel solution for its customers, with access to its cloud-based content management, master data management, and system-wide customer data,” according to the report.
In R&D, Vault Clinical, Vault RIM, and Vault Quality are helping companies streamline their end-to-end clinical trial processes, respond faster to business changes and health authority requests, and integrate their quality processes and content. Within commercial operations, Veeva Commercial Cloud is improving how life sciences companies bring together customer data, compliant content, and multichannel engagement to market and sell more effectively. While Veeva Medical Solutions help organizations discover, target, and engage the right opinion leaders.
“There is a significant shift occurring in the industry to cloud applications that streamline and unify business processes,” said Paul Shawah, vice president of product marketing at Veeva. “Our focus on industry-specific applications is helping our customers transform their R&D, commercial, and medical operations to support faster product launches and quickly adopt new business models. Industry analysts validate that we are gaining momentum as a strategic partner to the industry.”...."
"1 Stephen Davies (Gartner: March 18, 2016), Market Guide for CRM in Pharma and Biotech
2 As of April 30, 2016.
3 Stephen Davies (Gartner: March 18, 2016), Market Guide for CRM in Pharma and Biotech
4 Stephen Davies (Gartner: March 18, 2016), Market Guide for CRM in Pharma and Biotech
5 Alan S. Louie, Ph.D., Michael Townsend, Eric Newmark (IDC Health Insights: June 2016), Business Strategy: Top Software Vendors in the Life Science Industry, 2015"
Recent VEEV News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/15/2025 08:49:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/10/2025 03:03:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2025 08:59:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2025 08:58:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2025 08:57:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2025 08:56:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2025 08:56:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2025 08:55:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/04/2025 06:10:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2025 09:50:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2025 09:49:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2025 09:48:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2025 09:46:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2025 09:45:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/02/2025 08:12:40 PM
- Veeva Announces Research Site Clinical Trial Management System • PR Newswire (US) • 04/01/2025 11:03:00 AM
- Veeva Announces Research Site Clinical Trial Management System • PR Newswire (US) • 04/01/2025 11:03:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/24/2025 08:07:08 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/24/2025 08:05:48 PM
- Indero Marks 40th Study Live with Veeva RTSM • PR Newswire (US) • 03/19/2025 11:03:00 AM
- Indero Marks 40th Study Live with Veeva RTSM • PR Newswire (US) • 03/19/2025 11:03:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/14/2025 06:34:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2025 08:28:57 PM
- Boehringer Ingelheim Partners with Veeva to Launch 'One Medicine Platform' • PR Newswire (US) • 03/11/2025 11:03:00 AM
- Boehringer Ingelheim Partners with Veeva to Launch 'One Medicine Platform' • PR Newswire (US) • 03/11/2025 11:03:00 AM
FEATURED Cannabix Enters Sales Distribution Agreement with Alco Prevention Canada for BreathLogix Autonomous Alcohol Breathalyzer • Apr 28, 2025 8:49 AM
Veri Medtech (VRHI) Retains PCAOB Auditor • VRHI • Apr 28, 2025 8:30 AM
Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement • COEP • Apr 25, 2025 8:33 AM
UAV Corp. Successfully Completes Inflation Test of DART SA-70 Airship, Paving Way for Flight Readiness • UMAV • Apr 24, 2025 8:30 AM
InnerScope Hearing Technologies (OTC: INND) Announces the Grand Opening of OTCHealthMart.com • INND • Apr 24, 2025 8:00 AM
Opus Holdings Unveils Powerhouse Leadership Team to Drive Aggressive Growth and Transform Market Trajectory • CATV • Apr 22, 2025 8:30 AM